TiO2 nanoparticles tested in a novel screening whole human blood model of toxicity trigger adverse activation of the kallikrein system at low concentrations

Biomaterials

Volumn 51, Issue , 2015, Pages 58-68

  Ekstrand Hammarström, Barbro ^a   Hong, Jaan ^b   Davoodpour, Padideh ^b   Sandholm, Kerstin ^c   Ekdahl, Kristina N ^b,c   Bucht, Anders ^a,d   Nilsson, Bo ^b  

^a SWEDISH DEFENCE RESEARCH AGENCY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LINNAEUS UNIVERSITY   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

Author keywords

Complement; Contact system; Nanoparticles; P25; Platelets

Indexed keywords

ANIMALS; CHEMICAL ACTIVATION; NANOPARTICLES; OXIDE MINERALS; PLATELETS; TIO2 NANOPARTICLES; TITANIUM DIOXIDE; TOXICITY;

CHRONIC INFLAMMATION; COMPLEMENT; CONTACT SYSTEMS; INTERPRETATION OF EXPERIMENTS; LONG-TERM EFFECTS; LOW CONCENTRATIONS; NANOPARTICLE (NPS); TEST APPLICATIONS;

BLOOD;

BRADYKININ; KALLIKREIN; TITANIUM DIOXIDE NANOPARTICLE; ANTITHROMBIN III; ANTITHROMBIN III-PROTEASE COMPLEX; COMPLEMENT; NANOPARTICLE; PEPTIDE HYDROLASE; PLASMA PROTEIN; TITANIUM; TITANIUM DIOXIDE;

ARTERIOSCLEROSIS; ARTICLE; AUTOIMMUNITY; BLOOD; CHRONIC INFLAMMATION; EXPERIMENTAL MODEL; HUMAN; IN VIVO STUDY; INFLAMMATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; RISK; SCREENING TEST; SPECIES DIFFERENCE; TOXICITY; ADSORPTION; BIOLOGICAL MODEL; BLOOD CLOTTING; CHEMISTRY; DRUG EFFECTS; MASS SPECTROMETRY; METABOLISM; PATHOLOGY; TIME; ULTRASTRUCTURE;

ANIMALIA;

ADSORPTION; ANTITHROMBIN III; BLOOD COAGULATION; BLOOD PROTEINS; COMPLEMENT SYSTEM PROTEINS; HUMANS; INFLAMMATION; KALLIKREINS; MODELS, BIOLOGICAL; NANOPARTICLES; PEPTIDE HYDROLASES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TIME FACTORS; TITANIUM;

EID: 84924911596     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.01.031     Document Type: Article

References (51)

1. EU Commission recommendations of 18 October 2011 on the definition of nanomaterial (2011/696/EU). Off J 2011, L275:38-40.
2. Buzea C., Pacheco I.I., Robbie K. Nanomaterials and nanoparticles: sources and toxicity. Biointerphases 2007, 2:MR17-71.
3. Qui J. Nano-safety studies urged in China. Nature 2012, 489:350.
4. Kaur I., Kakkar V., Deol P., Yadav M., Singh M., Sharma I. Issues and concerns in nanotech product development and its commercialization. JControl Release 2014, 10.1016/j.jconrel.2014.06.005.
5. Bleeker E., de Jong W., Geertsma R., Groenewold M., Heugens E., Koers-Jacquemijns M., et al. Considerations on the EU definition of a nanomaterial: science to support policy making. Regul Toxicol Pharmacol 2013, 65:119-125.
6. Ong K., MacCormack T., Clark R., Ede J., Ortega V., Felix L., et al. Widespread nanoparticle-assay interference: implications for nanotoxicity testing. PLoS One 2014, 9:e90650.
7. Nemmar A., Hoet P.H., Vanquickenborne B., Dinsdale D., Thomeer M., Hoylaerts M.F., et al. Passage of inhaled particles into the blood circulation in humans. Circulation 2002, 105:411-414.
8. Geiser M., Kreyling W.G. Deposition and biokinetics of inhaled nanoparticles. Part Fibre Toxicol 2010, 7:2.
9. Wang J., Zhou G., Chen C., Yu H., Wang T., Ma Y., et al. Acute toxicity and biodistribution of different sized titanium dioxide particles in mice after oral administration. Toxicol Lett 2007, 168:176-185.
10. Newman M.D., Stotland M., Ellis J.I. The safety of nanosized particles in titanium dioxide- and zinc oxide-based sunscreens. JAm Acad Dermatol 2009, 61:685-692.
11. Monopoli M.P., Aberg C., Salvati A., Dawson K.A. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol 2012, 7:779-786.
12. Lundqvist M., Stigler J., Elia G., Lynch I., Cedervall T., Dawson K.A. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A 2008, 105:14265-14270.
13. Deng Z.J., Mortimer G., Schiller T., Musumeci A., Martin D., Minchin R.F. Differential plasma protein binding to metal oxide nanoparticles. Nanotechnology 2009, 20:455101.
14. Costa-Neto C.M., Dillenburg-Pilla P., Heinrich T.A., Parreiras-e-Silva L.T., Pereira M.G., Reis R.I., et al. Participation of kallikrein-kinin system in different pathologies. Int Immunopharmacol 2008, 8:135-142.
15. da Costa P., Sirois P., Tannock I., Chammas R. The role of kinin receptors in cancer and therapeutic opportunities. Cancer Lett 2014, 345:27-38.
16. Nilsson B., Ekdahl K.N., Mollnes T.E., Lambris J.D. The role of complement in biomaterial-induced inflammation. Mol Immunol 2007, 44:82-94.
17. Li N., Xia T., Nel A.E. The role of oxidative stress in ambient particulate matter-induced lung diseases and its implications in the toxicity of engineered nanoparticles. Free Radic Biol Med 2008, 44:1689-1699.
18. Gustafsson A., Lindstedt E., Elfsmark L.S., Bucht A. Lung exposure of titanium dioxide nanoparticles induces innate immune activation and long-lasting lymphocyte response in the Dark Agouti rat. JImmunotoxicol 2011, 8:111-121.
19. Ma-Hock L., Treumann S., Strauss V., Brill S., Luizi F., Mertler M., et al. Inhalation toxicity of multiwall carbon nanotubes in rats exposed for 3 months. Toxicol Sci Off J Soc Toxicol 2009, 112:468-481.
20. Shannahan J.H., Kodavanti U.P., Brown J.M. Manufactured and airborne nanoparticle cardiopulmonary interactions: a review of mechanisms and the possible contribution of mast cells. Inhal Toxicol 2012, 24:320-339.
21. Baccarelli A., Martinelli I., Zanobetti A., Grillo P., Hou L.F., Bertazzi P.A., et al. Exposure to particulate air pollution and risk of deep vein thrombosis. Arch Intern Med 2008, 168:920-927.
22. Dales R.E., Cakmak S., Vidal C.B. Air pollution and hospitalization for venous thromboembolic disease in Chile. JThromb Haemost 2010, 8:669-674.
23. Hoek G., Brunekreef B., Fischer P., van Wijnen J. The association between air pollution and heart failure, arrhythmia, embolism, thrombosis, and other cardiovascular causes of death in a time series study. Epidemiology 2001, 12:355-357.
24. Nel A.E., Madler L., Velegol D., Xia T., Hoek E.M., Somasundaran P., et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009, 8:543-557.
25. Oberdorster G., Oberdorster E., Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005, 113:823-839.
26. Andersson P.O., Lejon C., Ekstrand-Hammarstrom B., Akfur C., Ahlinder L., Bucht A., et al. Polymorph- and size-dependent uptake and toxicity of TiO(2) nanoparticles in living lung epithelial cells. Small 2011, 7:514-523.
27. Rappsilber J., Mann M., Ishihama Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc 2007, 2:1896-1906.
28. Sanchez J., Lundquist P.B., Elgue G., Larsson R., Olsson P. Measuring the degree of plasma contact activation induced by artificial materials. Thromb Res 2002, 105:407-412.
29. Nilsson Ekdahl K., Nilsson B., Pekna M., Nilsson U.R. Generation of iC3 at the interface between blood and gas. Scand J Immunol 1992, 35:85-91.
30. Mollnes T.E., Lea T., Harboe M., Tschopp J. Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol 1985, 22:183-195.
31. Ekdahl K.N., Hong J., Hamad O., Larsson R., Nilsson B. Evaluation of the blood compatibility of materials, cells and tissues: basic concepts, test models and practical guidelines. Adv Exp Biol Med 2013, 734:257-270.
32. Krajewski S., Prucek R., Panacek A., Avci-Adali M., Nolte A., Straub A., et al. Hemocompatibility evaluation of different silver nanoparticle concentrations employing a modified Chandler-loop invitro assay on human blood. Acta Biomater 2013, 9:7460-7468.
33. Liu Y., Cai D., Yang J., Wang Y., Zhang X., Yin S. Invitro hemocompatibility evaluation of poly (4-hydroxybutyrate) scaffold. Int J Clin Exp Med 2014, 7:1233-1243.
34. Mollnes T., Brekke O., Fung M., Fure H., Christiansen D., Bergseth G., et al. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002, 100:1869-1977.
35. Hulander M., Hong J., Andersson M., Gervén F., Ohrlander M., Tengvall P., et al. Blood interactions with noble metals: coagulation and immune complement activation. ACS Appl Mater Interfaces 2009, 1:1053-1062.
36. Kaida T., Kobayashi K., Adachi M., Suzuki F. Optical characteristics of titanium oxide interference film and the film laminated with oxides and their applications for cosmetics. JCosmet Sci 2004, 55:219-220.
37. 2 nanotubes on microstructured surfaces of blasted, screw-shaped titanium implants. Int J Nanomed 2010, 5:87-100.
38. Wolf R., Matz H., Orion E., Lipozencic J. Sunscreens - the ultimate cosmetic. Acta Dermatovenerol Croat 2003, 11:158-162.
39. Chen Y., Wan Y., Wang Y., Zhang H., Jiao Z. Anticancer efficacy enhancement and attenuation of side effects of doxorubicin with titanium dioxide nanoparticles. Int J Nanomed 2011, 6:2321-2326.
40. 2 nanoparticles co-doped with silver and nitrogen for antibacterial application. JNanosci Nanotechnol 2010, 10:4868-4874.
41. Hong J., Andersson J., Ekdahl K.N., Elgue G., Axen N., Larsson R., et al. Titanium is a highly thrombogenic biomaterial: possible implications for osteogenesis. Thromb Haemost 1999, 82:58-64.
42. Back J., Lood C., Bengtsson A.A., Ekdahl K.N., Nilsson B. Contact activation productsare new potential biomarkers to evaluate the risk of thrombotic events in systemic lupus erythematosus. Arthritis Res Ther 2013, 15:R206.
43. Ratnoff O.D., Crum J.D. Activation of Hageman factor by solutions of ellagic acid. JLab Clin Med 1964, 63:359-377.
44. Lee K., Park S., Mirkin C., Smith J., Mrksich M. Protein nanoarrays generated by dip-pen nanolithography. Science 2002, 295:1702-1705.
45. Janssen B.J., Huizinga E.G., Raaijmakers H.C.A., Roos A., Daha M.R., Ekdahl K.N., et al. Structures of complement component C3 and its fragment C3c. Nature 2005, 437:505-511.
46. Cool D., Edgell C., Louie G., Zoller M., Brayer G., MacGillivray R. Characterization of human blood coagulation factor XII cDNA. Prediction of the primary structure of factor XII and the tertiary structure of beta-factor XIIa. JBiol Chem 1985, 260:13666-13676.
47. Endo Y., Matsushita M., Fujita T. The role of ficolins in the lectin pathway of innate immunity. Int J Biochem Cell Biol 2011, 43:705-712.
48. Kilchherr E., Hofmann H., Steigemann W., Engel J. Structural model of the collagen-like region of C1q comprising the kink region and the fibre-like packing of the 6 triple helices. JMol Biol 1985, 186:403-415.
49. Andersson J., Ekdahl K.N., Larsson R., Nilsson U.R., Nilsson B. C3 adsorbed to a polymer surface can form an initiating alternative pathway convertase. JImmunol 2002, 168:5786-5791.
50. De Falco L., Fioravanti A., Galeazzi M., Tenti S. Bradykinin and its role in osteoarthritis. Reumatismo 2013, 65:97-104.
51. Göbel K., Pankratz S., Schneider-Hohendorf T., Bittner S., Schuhmann M., Langer H., et al. Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking. JAutoimmun 2011, 36:106-114.